arrow
R

Robert J. Commons

Menzies School of Health Research
H指数:28
被引数:2,550

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A cross-sectional study of the use of graduated compression stockings at two top end hospitals in Darwin, Australia

澳大利亚达尔文市两家顶级医院对梯度压缩袜使用情况的横断面研究

2026-06-011
OAAI
Systematic review and individual patient data meta-analysis on glucose-6-phosphate dehydrogenase activities measured by a semi-quantitative handheld biosensor

系统评价和基于半定量手持生物传感器测量的葡萄糖-6-磷酸脱氢酶活性的个体患者数据Meta分析

2025-11-200
OAAI
Automated reporting of primaquine dose efficacy, tolerability and safety for Plasmodium vivax malaria using a systematic review and individual patient data meta-analysis

使用系统综述和个体患者数据Meta分析,对伯氨喹剂量在间日疟中的疗效、耐受性和安全性进行自动化报告

2025-11-140
OAAI
Identifying heterogeneity of treatment effect for antibiotic duration in bloodstream infection: an exploratory post-hoc analysis of the BALANCE randomised clinical trial

识别血流感染中抗生素疗程的治疗效应异质性:BALANCE随机临床试验的探索性事后分析

2025-05-010
PRE
Within-host modeling of primaquine-induced hemolysis in hemizygote glucose-6-phosphate dehydrogenase deficient healthy volunteers

葡萄糖-6-磷酸脱氢酶半合子缺陷健康志愿者中伯喹诱发溶血的宿主内建模

2025-02-240
OAAI
Primaquine for uncomplicated Plasmodium vivax malaria in children younger than 15 years: a systematic review and individual patient data meta-analysis

Primaquine治疗15岁以下儿童的非复杂性间日疟: 系统评价和个体患者数据荟萃分析

2024-11-011
OAAI
Primaquine dose and the risk of haemolysis in patients with uncomplicated Plasmodium vivax malaria: a systematic review and individual patient data meta-analysis

Primaquine剂量和无并发症的间日疟患者的溶血风险: 系统评价和个体患者数据荟萃分析

2024-02-0112
OAAI
Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta

伯喹剂量对无并发症间日疟患者复发风险的影响: 系统评价和个体患者数据meta

2024-02-0113
OAAI
Safety and efficacy of primaquine in patients with Plasmodium vivax malaria from South Asia: a systematic review and individual patient data meta-analysis

伯喹治疗南亚间日疟患者的安全性和有效性: 系统评价和个体患者数据荟萃分析

2023-12-203
OAAI
The heterogeneity of symptom reporting across study sites: a secondary analysis of a randomised placebo-controlled multicentre antimalarial trial
2023-09-041
OAAI